Vivos Therapeutics (VVOS)

Obstructive sleep apnea is commonly associated with interrupted breathing during sleep, poor sleep quality, daytime fatigue, cardiovascular risk factors, and other health concerns. Standard treatment often involves continuous positive airway pressure machines, oral appliances, surgery, weight management, or combinations of therapies. Vivos positions its approach as non-surgical, non-invasive, and non-pharmaceutical, targeting patients who may not tolerate or prefer not to rely on conventional device-based therapies.

The Vivos System typically involves personalized oral appliance specifications and related clinical protocols intended to address airway and craniofacial factors that can contribute to sleep-disordered breathing. The company trains dentists and other providers in the use of its system and seeks to build a network of clinicians capable of identifying, treating, and managing appropriate patients. Its business model therefore depends not only on product adoption, but also on provider education, patient referrals, reimbursement dynamics, and clinical acceptance.

As a small-cap healthcare technology company, Vivos operates in a market with significant unmet need but also meaningful competition from established sleep medicine treatments and dental sleep appliance providers. Its prospects are tied to evidence supporting its protocols, regulatory and commercial execution, clinician uptake, and the broader awareness of sleep apnea diagnosis and treatment options.